aspirin and Local Neoplasm Recurrence
aspirin has been researched along with Local Neoplasm Recurrence in 95 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM)." | 9.41 | Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial. ( Angelsen, JH; Bjørnbeth, BA; Fristrup, CW; Grønbech, JE; Hemmingsson, O; Isaksson, B; Juel, IS; Larsen, PN; Lindell, G; Mortensen, FV; Mortensen, KE; Rizell, M; Sandström, P; Sandvik, OM; Sparrelid, E; Taflin, H; Taskén, K; Yaqub, S, 2021) |
" Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk." | 9.34 | Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. ( Ait-Omar, A; Benallaoua, M; Benamouzig, R; Boubaya, M; Deutsch, D; Helfen, S; Levy, V; Mary, F; Soualy, A, 2020) |
"In a prospective study, the combination of calcitriol, aspirin, and calcium carbonate did not prevent recurrence of colorectal adenomas over a 3-year period." | 9.22 | Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2016) |
"Aspirin has been shown to protect against colorectal neoplasms; however, the optimal chemopreventive dose and underlying mechanisms are unclear." | 9.20 | Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). ( Ahnen, DJ; Baron, JA; Barry, EL; Bradshaw, PT; Bresalier, RS; Fedirko, V; Figueiredo, JC; Milne, GL; Sandler, RS, 2015) |
"Study subjects, about half of whom were recruited after fortification of grain products with folic acid in the United States and Canada, consisted of 871 individuals with a recent history of one or more colorectal adenomas who were randomized to receive either a 1 mg/day folic acid supplement or a placebo within one of three randomly assigned aspirin treatment groups (placebo, 81, or 325 mg/day)." | 9.14 | Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation. ( Baron, JA; Grau, MV; Levine, AJ; Mott, LA; Ueland, PM, 2010) |
"Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas." | 9.14 | Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2010) |
" Aspirin inhibits COX-2 activity and lowers the risk for colorectal adenomas and cancer." | 9.14 | Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. ( Ahnen, DJ; Ali, IU; Baron, JA; Barry, EL; Bresalier, RS; Burke, C; Grau, MV; Gui, J; McKeown-Eyssen, GE; Munroe, DJ; Saibil, F; Sandler, RS; Sansbury, LB; Tsang, S, 2009) |
"The Aspirin/Folate Polyp Prevention Study is a randomized clinical trial of folic acid supplementation and incidence of new colorectal adenomas in individuals with a history of adenomas (n = 1,084)." | 9.13 | Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. ( Ahnen, DJ; Ali, I; Baron, JA; Barry, EL; Figueiredo, JC; Grau, MV; Haile, RW; Levine, AJ; Midttun, O; Munroe, D; Sandler, RS; Tsang, S; Ueland, PM, 2008) |
"8%) of 434 patients receiving aspirin had a recurrent adenoma compared with 121 (28." | 9.13 | Aspirin and folic acid for the prevention of recurrent colorectal adenomas. ( Armitage, NC; Grainge, MJ; Logan, RF; Muir, KR; Shepherd, VC, 2008) |
" The pooled relative risk (RR) with 95% confidence interval (CI) was used to estimate the effect of aspirin on colorectal cancer and/or colorectal adenomas." | 9.12 | Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials. ( Bhan, C; Cao, C; Cheng, C; Guo, Z; Han, T; Ji, Z; Ma, S; Qu, G; Sun, C; Yan, Y; Yang, H; Zhang, H; Zhou, Q, 2021) |
"The purpose of this study is to investigate whether aspirin improves the prognosis of breast cancer patients by meta analysis." | 9.12 | Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis. ( Liu, A; Liu, J; Wu, X; Yang, M; Zheng, F, 2021) |
"Among the 238 patients who completed the year 1 colonoscopy, at least one adenoma was observed in 38 patients of the 126 (30%) in the aspirin group and in 46 of the 112 (41%) in the placebo group; relative risk was 0." | 9.10 | Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Girard, B; Jullian, E; Little, J; Martin, A; Piednoir, B, 2003) |
" A multicentre, double-blind, randomized, controlled trial is underway to determine the efficacy of regular aspirin intake (160 or 300 mg/day) in reducing colorectal adenoma recurrence." | 9.09 | APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Little, J; Martin, A; Yoon, H, 2001) |
"In patients with a previous history of colorectal cancer or adenomas, low-dose aspirin (80-160 mg/day) compared to placebo taken for 2 to 4 years reduces the risk of recurrent colorectal adenomas (relative risk (RR), 0." | 8.95 | Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. ( Chaiyakunapruk, N; Ching, SM; Lim, KG; Phisalprapa, P; Saokaew, S; Veettil, SK, 2017) |
"Through search the possible randomized control trials, we make a renewed meta-analysis in order to assess the impact of aspirin in preventing the recurrence of colorectal adenoma." | 8.93 | The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials. ( Cheng, DW; Gao, XK; Lu, XJ; Luo, H; Tu, J; Wang, Y; Wang, YJ; Xu, XL; Yan, BC; Zhang, HL; Zhao, TY, 2016) |
"NSAIDs and aspirin after but not before diagnosis were associated with improved breast cancer survival, including breast-cancer-specific mortality, all-cause mortality, and relapse/metastasis." | 8.91 | Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. ( Chen, P; Chen, XW; Gao, P; Huang, XZ; Liu, J; Song, YX; Sun, JX; Tsai, CC; Wang, ZN; Xu, HM, 2015) |
"This meta-analysis suggests that aspirin prevents recurrent colorectal adenomas among patients with a history of colorectal adenomas." | 8.85 | The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2009) |
"We combined data from all randomized double-blind placebo-controlled trials that evaluated aspirin for the prevention of colorectal adenomas." | 8.85 | Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. ( Baron, JA; Benamouzig, R; Chaussade, S; Cole, BF; Grainge, MJ; Halabi, S; Logan, RF; Sandler, RS, 2009) |
"Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up." | 8.84 | Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. ( Flossmann, E; Rothwell, PM, 2007) |
"To determine the impact of fibrin clot inhibitor (FCI) use on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate bacille Calmette-Guérin (BCG)." | 8.12 | Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin? ( Bree, KK; Dinney, CP; Hensley, PJ; Kamat, AM; Lobo, N; Navai, N; Nogueras-Gonzalez, GM, 2022) |
" Here, we report the case of an 82-year-old Japanese woman with normal renal function who developed multiple cerebral infarctions due to CAT that grew rapidly, associated with inflammation from an antecedent infection, and diminished rapidly by detachment of fibrin on the mass surface and antithrombotic drugs." | 8.12 | Multiple cerebral infarctions due to calcified amorphous tumor growing rapidly from an antecedent infection and decreasing rapidly by detachment of fibrin and antithrombotic drugs: a case report. ( Doyu, M; Ito, H; Kimura, M; Matsuyama, K; Niwa, JI, 2022) |
" Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality." | 7.96 | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. ( Armstrong, K; Bardia, A; Chan, AT; He, W; Iafrate, AJ; Kumar, NP; McCarthy, AM; Moy, B; Regan, S; Welch, M, 2020) |
"Aspirin use may have chemo-preventive effect on recurrence of hepatitis B virus-related HCC after curative resection." | 7.96 | Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. ( Chao, Y; Chau, GY; Hou, MC; Huang, YH; Huo, TI; Lee, IC; Lee, MH; Lin, HC; Su, CW; Yeh, YC; Young, SH, 2020) |
"Results from previous studies indicate that use of low-dose aspirin may improve breast cancer prognosis." | 7.88 | No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. ( Ekberg, S; Eloranta, S; Fredriksson, I; Frisk, G; Lambe, M; Lidbrink, E; Smedby, KE; Sund, M, 2018) |
"Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective COX-2 inhibitors may improve outcomes in breast cancer patients." | 7.83 | Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence. ( Ahern, TP; Christiansen, P; Cronin-Fenton, DP; Ejlertsen, B; Heide-Jørgensen, U; Lash, TL; Sørensen, HT, 2016) |
"The impact of statins, aspirin and metformin use on recurrence-free (RFS) and overall survival (OS) of patients with biliary tract cancer (BTC) has not been evaluated." | 7.81 | Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer. ( Aneja, P; Horgan, AM; Knox, JJ; Le, LW; McKeever, E; McNamara, MG, 2015) |
"This study aimed to evaluate the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones." | 7.81 | Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. ( Al Salhi, Y; Carbone, A; Costantini, E; de Nunzio, C; Fuschi, A; Palleschi, G; Pastore, A; Petrozza, V; Silvestri, L; Zucchi, A, 2015) |
"Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer." | 7.80 | Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014) |
"Recent observational studies suggest that postoperative aspirin use may improve Colorectal cancer (CRC)-specific survival and overall survival (OS)." | 7.80 | Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. ( Chew, L; Chew, MH; Chia, WK; Fu, WP; Goh, CH; Goh, HH; Leong, WQ; Pan, YS; Tan, IB; Tang, CL; Toh, HC; Tony, LK, 2014) |
"Aspirin is associated with a reduced risk of developing colorectal cancer." | 7.79 | Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. ( Donnan, PT; McCowan, C; Munro, AJ; Steele, RJ, 2013) |
"To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-Guérin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms." | 7.75 | Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. ( Bruskewitz, RC; Gee, JR; Hedican, SP; Jarrard, DF; Leverson, GE; Messing, EM; Moon, TD; Nakada, SY, 2009) |
"We genotyped ODC G316A in 546 individuals in the United Kingdom Colorectal Adenoma Prevention trial of aspirin for CRA recurrence prevention and pooled our findings with data from two other randomized intervention trials." | 7.74 | Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR, 2008) |
"Aspirin intolerance (AI) is characterized by polypous rhinosinusitis, bronchial asthma and adverse reactions to aspirin." | 7.70 | Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. ( Göde, U; Schäfer, D; Schmid, M; Wigand, ME, 1999) |
"However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy." | 6.90 | Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial). ( Fukuda, H; Hamaguchi, T; Kanemitsu, Y; Katayama, H; Miyamoto, K; Mizusawa, J; Nakamura, K; Sato, Y; Shibata, T; Shida, D; Shimada, Y; Takashima, A, 2019) |
"Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel." | 6.43 | Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. ( Benamouzig, R; Chaussade, S; Little, J; Uzzan, B, 2005) |
"The aim of this study was to determine the effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and to determine whether smoking modifies the effect of clopidogrel-based DAPT on subsequent stroke risk." | 5.69 | Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, A; Lang, AE; Mac Grory, B; Shu, L; Yaghi, S, 2023) |
"The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM)." | 5.41 | Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial. ( Angelsen, JH; Bjørnbeth, BA; Fristrup, CW; Grønbech, JE; Hemmingsson, O; Isaksson, B; Juel, IS; Larsen, PN; Lindell, G; Mortensen, FV; Mortensen, KE; Rizell, M; Sandström, P; Sandvik, OM; Sparrelid, E; Taflin, H; Taskén, K; Yaqub, S, 2021) |
"The occurrence of metastasis was ascertained monthly by a qualified oncologist, and confirmed, if necessary, by biopsy." | 5.36 | Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected]. ( Bhattacharyya, M; Chakraborty, S; Ghosh, R; Girish, GV; Sinha, AK, 2010) |
" Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk." | 5.34 | Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. ( Ait-Omar, A; Benallaoua, M; Benamouzig, R; Boubaya, M; Deutsch, D; Helfen, S; Levy, V; Mary, F; Soualy, A, 2020) |
"In a prospective study, the combination of calcitriol, aspirin, and calcium carbonate did not prevent recurrence of colorectal adenomas over a 3-year period." | 5.22 | Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2016) |
"Aspirin has been shown to protect against colorectal neoplasms; however, the optimal chemopreventive dose and underlying mechanisms are unclear." | 5.20 | Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). ( Ahnen, DJ; Baron, JA; Barry, EL; Bradshaw, PT; Bresalier, RS; Fedirko, V; Figueiredo, JC; Milne, GL; Sandler, RS, 2015) |
" Aspirin or heparin was recommended for patients at high thrombosis risk." | 5.20 | Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). ( Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN, 2015) |
"311 subjects with single/multiple colorectal adenomas and adenocarcinomas excised by endoscopy were enrolled in the study (152 patients in the aspirin group and 159 patients in the placebo group)." | 5.19 | The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. ( Abe, T; Gondo, N; Goto, C; Iimuro, M; Ishikawa, H; Joh, T; Kitamura, S; Kudo, SE; Kusunoki, M; Lee, K; Matsuda, T; Matsuura, N; Mizuno, M; Mutoh, M; Okamura, S; Saida, Y; Sakai, T; Sano, Y; Sato, Y; Sugimoto, K; Suzuki, S; Tajika, M; Takayama, T; Tanaka, S; Tokudome, S; Wakabayashi, K; Yukawa, T, 2014) |
"Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC) and are associated with reduced disease recurrence and improved outcome after primary treatment." | 5.17 | Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. ( Church, DN; Davidson, B; Domingo, E; Johnstone, E; Kerr, DJ; Midgley, R; Ramamoorthy, R; Sieber, O; Tomlinson, IP; Yanagisawa, Y, 2013) |
"Study subjects, about half of whom were recruited after fortification of grain products with folic acid in the United States and Canada, consisted of 871 individuals with a recent history of one or more colorectal adenomas who were randomized to receive either a 1 mg/day folic acid supplement or a placebo within one of three randomly assigned aspirin treatment groups (placebo, 81, or 325 mg/day)." | 5.14 | Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation. ( Baron, JA; Grau, MV; Levine, AJ; Mott, LA; Ueland, PM, 2010) |
" Aspirin inhibits COX-2 activity and lowers the risk for colorectal adenomas and cancer." | 5.14 | Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. ( Ahnen, DJ; Ali, IU; Baron, JA; Barry, EL; Bresalier, RS; Burke, C; Grau, MV; Gui, J; McKeown-Eyssen, GE; Munroe, DJ; Saibil, F; Sandler, RS; Sansbury, LB; Tsang, S, 2009) |
"Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas." | 5.14 | Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2010) |
"The Aspirin/Folate Polyp Prevention Study is a randomized clinical trial of folic acid supplementation and incidence of new colorectal adenomas in individuals with a history of adenomas (n = 1,084)." | 5.13 | Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. ( Ahnen, DJ; Ali, I; Baron, JA; Barry, EL; Figueiredo, JC; Grau, MV; Haile, RW; Levine, AJ; Midttun, O; Munroe, D; Sandler, RS; Tsang, S; Ueland, PM, 2008) |
" We assessed the association between two common MTHFR variants, 677C>T and 1298A>C, and adenoma recurrence in the context of a randomized double- blind clinical trial of aspirin use and folate supplementation." | 5.13 | MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial. ( Ahnen, D; Ali, IU; Baron, JA; Barry, EL; Cole, BF; Haile, RW; Levine, AJ; Munroe, DJ; Saibil, F; Tsang, S; Ueland, P; Wallace, K, 2008) |
"8%) of 434 patients receiving aspirin had a recurrent adenoma compared with 121 (28." | 5.13 | Aspirin and folic acid for the prevention of recurrent colorectal adenomas. ( Armitage, NC; Grainge, MJ; Logan, RF; Muir, KR; Shepherd, VC, 2008) |
"The purpose of this study is to investigate whether aspirin improves the prognosis of breast cancer patients by meta analysis." | 5.12 | Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis. ( Liu, A; Liu, J; Wu, X; Yang, M; Zheng, F, 2021) |
" The pooled relative risk (RR) with 95% confidence interval (CI) was used to estimate the effect of aspirin on colorectal cancer and/or colorectal adenomas." | 5.12 | Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials. ( Bhan, C; Cao, C; Cheng, C; Guo, Z; Han, T; Ji, Z; Ma, S; Qu, G; Sun, C; Yan, Y; Yang, H; Zhang, H; Zhou, Q, 2021) |
" Functional polymorphisms of UGT1A6 (T181A and R184S) and CYP2C9 (R144C and I359L) have been reported to modify the protective effect of aspirin on colorectal adenoma risk." | 5.12 | Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. ( Armitage, N; Grainge, M; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR; Popat, S; Shepherd, V, 2006) |
"Among the 238 patients who completed the year 1 colonoscopy, at least one adenoma was observed in 38 patients of the 126 (30%) in the aspirin group and in 46 of the 112 (41%) in the placebo group; relative risk was 0." | 5.10 | Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Girard, B; Jullian, E; Little, J; Martin, A; Piednoir, B, 2003) |
" A multicentre, double-blind, randomized, controlled trial is underway to determine the efficacy of regular aspirin intake (160 or 300 mg/day) in reducing colorectal adenoma recurrence." | 5.09 | APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Little, J; Martin, A; Yoon, H, 2001) |
"In patients with a previous history of colorectal cancer or adenomas, low-dose aspirin (80-160 mg/day) compared to placebo taken for 2 to 4 years reduces the risk of recurrent colorectal adenomas (relative risk (RR), 0." | 4.95 | Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. ( Chaiyakunapruk, N; Ching, SM; Lim, KG; Phisalprapa, P; Saokaew, S; Veettil, SK, 2017) |
"Through search the possible randomized control trials, we make a renewed meta-analysis in order to assess the impact of aspirin in preventing the recurrence of colorectal adenoma." | 4.93 | The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials. ( Cheng, DW; Gao, XK; Lu, XJ; Luo, H; Tu, J; Wang, Y; Wang, YJ; Xu, XL; Yan, BC; Zhang, HL; Zhao, TY, 2016) |
"NSAIDs and aspirin after but not before diagnosis were associated with improved breast cancer survival, including breast-cancer-specific mortality, all-cause mortality, and relapse/metastasis." | 4.91 | Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. ( Chen, P; Chen, XW; Gao, P; Huang, XZ; Liu, J; Song, YX; Sun, JX; Tsai, CC; Wang, ZN; Xu, HM, 2015) |
"This meta-analysis suggests that aspirin prevents recurrent colorectal adenomas among patients with a history of colorectal adenomas." | 4.85 | The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2009) |
"We combined data from all randomized double-blind placebo-controlled trials that evaluated aspirin for the prevention of colorectal adenomas." | 4.85 | Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. ( Baron, JA; Benamouzig, R; Chaussade, S; Cole, BF; Grainge, MJ; Halabi, S; Logan, RF; Sandler, RS, 2009) |
"Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up." | 4.84 | Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. ( Flossmann, E; Rothwell, PM, 2007) |
" Here, we report the case of an 82-year-old Japanese woman with normal renal function who developed multiple cerebral infarctions due to CAT that grew rapidly, associated with inflammation from an antecedent infection, and diminished rapidly by detachment of fibrin on the mass surface and antithrombotic drugs." | 4.12 | Multiple cerebral infarctions due to calcified amorphous tumor growing rapidly from an antecedent infection and decreasing rapidly by detachment of fibrin and antithrombotic drugs: a case report. ( Doyu, M; Ito, H; Kimura, M; Matsuyama, K; Niwa, JI, 2022) |
"To determine the impact of fibrin clot inhibitor (FCI) use on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate bacille Calmette-Guérin (BCG)." | 4.12 | Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin? ( Bree, KK; Dinney, CP; Hensley, PJ; Kamat, AM; Lobo, N; Navai, N; Nogueras-Gonzalez, GM, 2022) |
" Aspirin use post-diagnosis may modify components of the PI3K pathway, including AKT and mTOR, and has been associated with lower risk of breast cancer recurrence and mortality." | 3.96 | Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. ( Armstrong, K; Bardia, A; Chan, AT; He, W; Iafrate, AJ; Kumar, NP; McCarthy, AM; Moy, B; Regan, S; Welch, M, 2020) |
"Aspirin use may have chemo-preventive effect on recurrence of hepatitis B virus-related HCC after curative resection." | 3.96 | Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. ( Chao, Y; Chau, GY; Hou, MC; Huang, YH; Huo, TI; Lee, IC; Lee, MH; Lin, HC; Su, CW; Yeh, YC; Young, SH, 2020) |
"Our findings suggest that concurrent use of glucocorticoids, ACE inhibitors, aspirin, NSAIDs, selective COX-2 inhibitors, digoxin, and opioids has little impact on breast cancer recurrence." | 3.88 | Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. ( Ahern, TP; Christiansen, P; Cronin-Fenton, D; Damkier, P; Ejlertsen, B; Lash, TL; Sørensen, HT, 2018) |
"Results from previous studies indicate that use of low-dose aspirin may improve breast cancer prognosis." | 3.88 | No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. ( Ekberg, S; Eloranta, S; Fredriksson, I; Frisk, G; Lambe, M; Lidbrink, E; Smedby, KE; Sund, M, 2018) |
"Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective COX-2 inhibitors may improve outcomes in breast cancer patients." | 3.83 | Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence. ( Ahern, TP; Christiansen, P; Cronin-Fenton, DP; Ejlertsen, B; Heide-Jørgensen, U; Lash, TL; Sørensen, HT, 2016) |
"The impact of statins, aspirin and metformin use on recurrence-free (RFS) and overall survival (OS) of patients with biliary tract cancer (BTC) has not been evaluated." | 3.81 | Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer. ( Aneja, P; Horgan, AM; Knox, JJ; Le, LW; McKeever, E; McNamara, MG, 2015) |
"This study aimed to evaluate the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones." | 3.81 | Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. ( Al Salhi, Y; Carbone, A; Costantini, E; de Nunzio, C; Fuschi, A; Palleschi, G; Pastore, A; Petrozza, V; Silvestri, L; Zucchi, A, 2015) |
"Recent observational studies suggest that postoperative aspirin use may improve Colorectal cancer (CRC)-specific survival and overall survival (OS)." | 3.80 | Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. ( Chew, L; Chew, MH; Chia, WK; Fu, WP; Goh, CH; Goh, HH; Leong, WQ; Pan, YS; Tan, IB; Tang, CL; Toh, HC; Tony, LK, 2014) |
"Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer." | 3.80 | Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014) |
"Aspirin is associated with a reduced risk of developing colorectal cancer." | 3.79 | Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. ( Donnan, PT; McCowan, C; Munro, AJ; Steele, RJ, 2013) |
"To determine if there is a difference in clinical outcomes among non-muscle-invasive bladder cancer patients taking fibrin clot-inhibiting (FCI) medications (aspirin, clopidogrel, or warfarin) while receiving Bacillus Calmette-Guérin (BCG) therapy compared with their counterparts not taking anticoagulation." | 3.79 | The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer. ( Badalato, GM; Hruby, GW; Lipsky, MJ; McKiernan, JM; Motamedinia, P, 2013) |
"To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-Guérin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms." | 3.75 | Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. ( Bruskewitz, RC; Gee, JR; Hedican, SP; Jarrard, DF; Leverson, GE; Messing, EM; Moon, TD; Nakada, SY, 2009) |
"We genotyped ODC G316A in 546 individuals in the United Kingdom Colorectal Adenoma Prevention trial of aspirin for CRA recurrence prevention and pooled our findings with data from two other randomized intervention trials." | 3.74 | Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR, 2008) |
"Aspirin intolerance (AI) is characterized by polypous rhinosinusitis, bronchial asthma and adverse reactions to aspirin." | 3.70 | Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. ( Göde, U; Schäfer, D; Schmid, M; Wigand, ME, 1999) |
"However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy." | 2.90 | Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial). ( Fukuda, H; Hamaguchi, T; Kanemitsu, Y; Katayama, H; Miyamoto, K; Mizusawa, J; Nakamura, K; Sato, Y; Shibata, T; Shida, D; Shimada, Y; Takashima, A, 2019) |
"Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts." | 2.82 | ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. ( Berkman, L; Cafferty, FH; Cameron, D; Coyle, C; Gilbert, D; Gupta, S; Kynaston, H; Langley, RE; MacKenzie, M; Pramesh, CS; Ring, A; Rowley, S; Wilson, RH, 2016) |
"Aspirin is a commonly used medication with anti-inflammatory and analgesic properties, and it is widely used to reduce the risk of ischaemic heart disease-related events and/or cerebrovascular accidents." | 2.72 | The multiple effects of aspirin in prostate cancer patients. ( Bryant, RJ; Joshi, SN; Murphy, EA; Olaniyi, P, 2021) |
"Metformin use was associated with a significantly higher overall and disease-free survival, in a subset of diabetic patients." | 2.55 | Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. ( Chambers, AC; Cotton, DE; Gash, KJ; Thomas, MG; Williams, AC, 2017) |
"Breast cancer is the most common cancer in women worldwide." | 2.52 | Update on breast cancer risk prediction and prevention. ( Cuzick, J; Sestak, I, 2015) |
"Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel." | 2.43 | Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. ( Benamouzig, R; Chaussade, S; Little, J; Uzzan, B, 2005) |
" As well, we highlight current research around optimal dosage and other issues related to aspirin administration." | 2.43 | What every emergency nurse needs to know about aspirin. ( Smith, S; Turris, SA, 2005) |
"In addition to residual cancer cells, the surgery resection-induced hyperinflammatory microenvironment is a key factor that leads to postsurgical cancer recurrence." | 1.91 | Aspirin-Loaded Cross-Linked Lipoic Acid Nanodrug Prevents Postoperative Tumor Recurrence by Residual Cancer Cell Killing and Inflammatory Microenvironment Improvement. ( Chen, Y; Jing, P; Liao, C; Luo, Y; Tan, J; Zhang, S, 2023) |
"Aspirin or NSAID use was considered positive if the patients were receiving aspirin or NSAID medication from HNSCC diagnosis to at least 1 year after treatment initiation." | 1.48 | Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up. ( Choi, SH; Kim, SA; Kim, SB; Kim, SY; Nam, SY; Roh, JL, 2018) |
"Aspirin users were significantly older, more likely to have a history of cardiovascular disease and diabetes, and more likely to use metformin or statin (each p <0." | 1.48 | The Association of Aspirin Use with Survival Following Radical Cystectomy. ( Boorjian, SA; Cheville, JC; Frank, I; Karnes, RJ; Lyon, TD; Shah, PH; Tarrell, R; Thompson, RH; Tollefson, MK, 2018) |
"Recurrence of hepatocellular carcinoma (HCC) with unsatisfactory survival is common after surgical resection." | 1.43 | Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. ( Chao, Y; Chen, CC; Chen, TJ; Hu, YW; Huang, YH; Huo, TI; Lee, PC; Lin, HC; Liu, CJ; Su, CW; Wu, JC; Yeh, CM, 2016) |
" Further study is needed to confirm these findings and to determine the optimal dosing and schedule, as well as the relative benefits and risks, of both therapies in combination with RT." | 1.38 | Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. ( Buyyounouski, MK; Horwitz, EM; Li, T; Zaorsky, NG, 2012) |
"The occurrence of metastasis was ascertained monthly by a qualified oncologist, and confirmed, if necessary, by biopsy." | 1.36 | Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected]. ( Bhattacharyya, M; Chakraborty, S; Ghosh, R; Girish, GV; Sinha, AK, 2010) |
"Ovarian cancer is a gynecological malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment." | 1.33 | Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. ( Bratasz, A; Ignarro, LJ; Kuppusamy, P; Parinandi, NL; Sridhar, R; Weir, NM; Zweier, JL, 2006) |
"Acute in-stent thrombosis is a well-known complication of carotid angioplasty and stenting (CAS) and often due to resistance to or inadequate treatment with platelet-inhibiting agents." | 1.33 | Late in-stent thrombosis following carotid angioplasty and stenting. ( Buhk, JH; Knauth, M; Wellmer, A, 2006) |
"To prospectively examine the association between non-steroidal anti-inflammatory drugs (NSAIDs) use (including dose and dosage schedule) and the recurrence of colorectal adenomas among individuals who were diagnosed with an adenoma at entry into a clinical trial." | 1.32 | Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). ( Albert, PS; Burt, R; Caan, B; Corle, D; Hasson, M; Iber, F; Kikendall, JW; Lance, P; Lanza, E; Paskett, E; Schatzkin, A; Shike, M; Tangrea, JA; Weissfeld, J; Woodson, K, 2003) |
"Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread." | 1.30 | [How I treat colorectal cancer. I. Prevention and adjuvant treatment]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
"Bronchial asthma was diagnosed in 40% of all patients." | 1.28 | Recurrence of nasal polyps after surgical treatment. ( Holopainen, E; Jäntti-Alanko, S; Malmberg, H, 1989) |
Research
Studies (95)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (5.26) | 18.7374 |
1990's | 5 (5.26) | 18.2507 |
2000's | 25 (26.32) | 29.6817 |
2010's | 44 (46.32) | 24.3611 |
2020's | 16 (16.84) | 2.80 |
Authors
Authors | Studies |
---|---|
Yaqub, S | 1 |
Bjørnbeth, BA | 1 |
Angelsen, JH | 1 |
Fristrup, CW | 1 |
Grønbech, JE | 1 |
Hemmingsson, O | 1 |
Isaksson, B | 1 |
Juel, IS | 1 |
Larsen, PN | 1 |
Lindell, G | 1 |
Mortensen, FV | 1 |
Mortensen, KE | 1 |
Rizell, M | 1 |
Sandström, P | 1 |
Sandvik, OM | 1 |
Sparrelid, E | 1 |
Taflin, H | 1 |
Taskén, K | 1 |
Chen, Y | 2 |
Zhang, Y | 1 |
Chen, S | 1 |
Liu, W | 1 |
Lin, Y | 1 |
Zhang, H | 2 |
Yu, F | 1 |
Lobo, N | 1 |
Hensley, PJ | 1 |
Bree, KK | 1 |
Nogueras-Gonzalez, GM | 1 |
Navai, N | 1 |
Dinney, CP | 1 |
Kamat, AM | 1 |
Kimura, M | 1 |
Niwa, JI | 1 |
Ito, H | 1 |
Matsuyama, K | 1 |
Doyu, M | 1 |
Wang, A | 1 |
Meng, X | 1 |
Tian, X | 1 |
Zuo, Y | 1 |
Bath, PM | 1 |
Li, H | 1 |
Xie, X | 1 |
Jing, J | 1 |
Lin, J | 1 |
Wang, Y | 3 |
Zhao, X | 1 |
Liu, L | 2 |
Li, Z | 1 |
Jiang, Y | 1 |
Xu, J | 1 |
Wang, F | 1 |
Chen, W | 1 |
Cao, M | 1 |
Li, J | 1 |
Jing, P | 1 |
Luo, Y | 1 |
Tan, J | 1 |
Liao, C | 2 |
Zhang, S | 1 |
Lang, AE | 1 |
de Havenon, A | 1 |
Mac Grory, B | 1 |
Henninger, N | 1 |
Shu, L | 1 |
Furie, KL | 1 |
Easton, JD | 1 |
Kim, A | 1 |
Johnston, SC | 1 |
Yaghi, S | 1 |
Miyamoto, K | 1 |
Takashima, A | 1 |
Mizusawa, J | 1 |
Sato, Y | 3 |
Shimada, Y | 1 |
Katayama, H | 1 |
Nakamura, K | 1 |
Shibata, T | 1 |
Fukuda, H | 1 |
Shida, D | 1 |
Kanemitsu, Y | 1 |
Hamaguchi, T | 1 |
McCarthy, AM | 1 |
Kumar, NP | 1 |
He, W | 1 |
Regan, S | 1 |
Welch, M | 1 |
Moy, B | 1 |
Iafrate, AJ | 1 |
Chan, AT | 4 |
Bardia, A | 1 |
Armstrong, K | 1 |
Soualy, A | 1 |
Deutsch, D | 1 |
Benallaoua, M | 1 |
Ait-Omar, A | 1 |
Mary, F | 1 |
Helfen, S | 1 |
Boubaya, M | 1 |
Levy, V | 1 |
Benamouzig, R | 6 |
Joshi, SN | 1 |
Murphy, EA | 1 |
Olaniyi, P | 1 |
Bryant, RJ | 1 |
Liang, PS | 1 |
Shaukat, A | 1 |
Crockett, SD | 2 |
Ma, S | 1 |
Han, T | 1 |
Sun, C | 1 |
Cheng, C | 1 |
Qu, G | 1 |
Bhan, C | 1 |
Yang, H | 1 |
Guo, Z | 1 |
Yan, Y | 1 |
Cao, C | 1 |
Ji, Z | 1 |
Zhou, Q | 1 |
Saka-Herrán, C | 1 |
Jané-Salas, E | 1 |
Estrugo-Devesa, A | 1 |
López-López, J | 1 |
Ishikawa, H | 2 |
Mutoh, M | 2 |
Doyama, H | 1 |
Tajika, M | 2 |
Tanaka, S | 2 |
Horimatsu, T | 1 |
Takeuchi, Y | 1 |
Kashida, H | 1 |
Tashiro, J | 1 |
Ezoe, Y | 1 |
Nakajima, T | 1 |
Ikematsu, H | 1 |
Hori, S | 1 |
Suzuki, S | 2 |
Otani, T | 1 |
Takayama, T | 2 |
Ohda, Y | 1 |
Mure, K | 1 |
Wakabayashi, K | 2 |
Sakai, T | 2 |
Liu, J | 2 |
Zheng, F | 1 |
Yang, M | 1 |
Wu, X | 1 |
Liu, A | 1 |
Gash, KJ | 1 |
Chambers, AC | 1 |
Cotton, DE | 1 |
Williams, AC | 1 |
Thomas, MG | 1 |
Kim, SA | 1 |
Roh, JL | 1 |
Kim, SB | 1 |
Choi, SH | 1 |
Nam, SY | 1 |
Kim, SY | 1 |
Veettil, SK | 1 |
Lim, KG | 1 |
Ching, SM | 1 |
Saokaew, S | 1 |
Phisalprapa, P | 1 |
Chaiyakunapruk, N | 1 |
Cronin-Fenton, D | 1 |
Lash, TL | 2 |
Ahern, TP | 2 |
Damkier, P | 1 |
Christiansen, P | 2 |
Ejlertsen, B | 2 |
Sørensen, HT | 2 |
Michel, P | 1 |
Boige, V | 1 |
Andre, T | 1 |
Aparicio, T | 1 |
Bachet, JB | 1 |
Dahan, L | 1 |
Guimbaud, R | 1 |
Lepage, C | 1 |
Manfredi, S | 1 |
Tougeron, D | 1 |
Taieb, J | 1 |
Selves, J | 1 |
Le Malicot, K | 1 |
Di Fiore, F | 1 |
Maillard, E | 1 |
Hawk, E | 1 |
Maresso, KC | 1 |
Brown, P | 1 |
Lyon, TD | 1 |
Frank, I | 1 |
Shah, PH | 1 |
Tarrell, R | 1 |
Cheville, JC | 1 |
Karnes, RJ | 1 |
Thompson, RH | 1 |
Tollefson, MK | 1 |
Boorjian, SA | 1 |
Mohammed, A | 1 |
Yarla, NS | 1 |
Madka, V | 1 |
Rao, CV | 1 |
Frisk, G | 1 |
Ekberg, S | 1 |
Lidbrink, E | 1 |
Eloranta, S | 1 |
Sund, M | 1 |
Fredriksson, I | 1 |
Lambe, M | 1 |
Smedby, KE | 1 |
Khoo, BL | 1 |
Grenci, G | 1 |
Lim, JSY | 1 |
Lim, YP | 1 |
Fong, J | 1 |
Yeap, WH | 1 |
Bin Lim, S | 1 |
Chua, SL | 1 |
Wong, SC | 1 |
Yap, YS | 1 |
Lee, SC | 1 |
Lim, CT | 1 |
Han, J | 1 |
Young, SH | 1 |
Chau, GY | 1 |
Lee, IC | 1 |
Yeh, YC | 1 |
Chao, Y | 2 |
Huo, TI | 2 |
Su, CW | 2 |
Lin, HC | 2 |
Hou, MC | 1 |
Lee, MH | 1 |
Huang, YH | 2 |
Tuyaerts, S | 1 |
Van Nuffel, AMT | 1 |
Naert, E | 1 |
Van Dam, PA | 1 |
Vuylsteke, P | 1 |
De Caluwé, A | 1 |
Aspeslagh, S | 1 |
Dirix, P | 1 |
Lippens, L | 1 |
De Jaeghere, E | 1 |
Amant, F | 1 |
Vandecasteele, K | 1 |
Denys, H | 1 |
Lipsky, MJ | 1 |
Badalato, GM | 1 |
Motamedinia, P | 1 |
Hruby, GW | 1 |
McKiernan, JM | 1 |
Domingo, E | 1 |
Church, DN | 1 |
Sieber, O | 1 |
Ramamoorthy, R | 1 |
Yanagisawa, Y | 1 |
Johnstone, E | 1 |
Davidson, B | 1 |
Kerr, DJ | 1 |
Tomlinson, IP | 1 |
Midgley, R | 1 |
Fuchs, CS | 3 |
Ogino, S | 2 |
Tokudome, S | 1 |
Saida, Y | 1 |
Abe, T | 1 |
Okamura, S | 1 |
Joh, T | 1 |
Kudo, SE | 1 |
Matsuda, T | 1 |
Iimuro, M | 1 |
Yukawa, T | 1 |
Lee, K | 1 |
Kitamura, S | 1 |
Mizuno, M | 1 |
Sano, Y | 1 |
Gondo, N | 1 |
Sugimoto, K | 1 |
Kusunoki, M | 1 |
Goto, C | 1 |
Matsuura, N | 1 |
Kirstein, MM | 1 |
Vogel, A | 1 |
Soon, SS | 1 |
Chia, WK | 2 |
Chan, ML | 1 |
Ho, GF | 1 |
Jian, X | 1 |
Deng, YH | 1 |
Tan, CS | 1 |
Sharma, A | 1 |
Segelov, E | 1 |
Mehta, S | 1 |
Ali, R | 1 |
Toh, HC | 2 |
Wee, HL | 1 |
Ng, K | 2 |
Meyerhardt, JA | 1 |
Sato, K | 1 |
Chan, JA | 1 |
Niedzwiecki, D | 1 |
Saltz, LB | 1 |
Mayer, RJ | 1 |
Benson, AB | 1 |
Schaefer, PL | 1 |
Whittom, R | 1 |
Hantel, A | 1 |
Goldberg, RM | 1 |
Venook, AP | 1 |
Giovannucci, EL | 1 |
Goh, CH | 1 |
Goh, HH | 1 |
Leong, WQ | 1 |
Chew, MH | 1 |
Pan, YS | 1 |
Tony, LK | 1 |
Chew, L | 1 |
Tan, IB | 1 |
Tang, CL | 1 |
Fu, WP | 1 |
Sestak, I | 1 |
Cuzick, J | 1 |
Harris, K | 1 |
Kebbe, J | 1 |
Huang, XZ | 1 |
Gao, P | 1 |
Sun, JX | 1 |
Song, YX | 1 |
Tsai, CC | 1 |
Chen, XW | 1 |
Chen, P | 1 |
Xu, HM | 1 |
Wang, ZN | 1 |
Pastore, A | 1 |
Palleschi, G | 1 |
Fuschi, A | 1 |
Silvestri, L | 1 |
Al Salhi, Y | 1 |
Costantini, E | 1 |
Zucchi, A | 1 |
Petrozza, V | 1 |
de Nunzio, C | 1 |
Carbone, A | 1 |
Lee, M | 1 |
Gibbs, P | 1 |
Fedirko, V | 1 |
Bradshaw, PT | 1 |
Figueiredo, JC | 2 |
Sandler, RS | 4 |
Barry, EL | 4 |
Ahnen, DJ | 3 |
Milne, GL | 1 |
Bresalier, RS | 2 |
Baron, JA | 8 |
Leonard, JP | 1 |
Jung, SH | 1 |
Johnson, J | 1 |
Pitcher, BN | 1 |
Bartlett, NL | 1 |
Blum, KA | 1 |
Czuczman, M | 1 |
Giguere, JK | 1 |
Cheson, BD | 1 |
Pommergaard, HC | 1 |
Burcharth, J | 1 |
Rosenberg, J | 1 |
Raskov, H | 1 |
McNamara, MG | 1 |
Aneja, P | 1 |
Le, LW | 1 |
Horgan, AM | 1 |
McKeever, E | 1 |
Knox, JJ | 1 |
Cronin-Fenton, DP | 1 |
Heide-Jørgensen, U | 1 |
Zhao, TY | 1 |
Tu, J | 1 |
Cheng, DW | 1 |
Gao, XK | 1 |
Luo, H | 1 |
Yan, BC | 1 |
Xu, XL | 1 |
Zhang, HL | 1 |
Lu, XJ | 1 |
Wang, YJ | 1 |
Lee, PC | 1 |
Yeh, CM | 1 |
Hu, YW | 1 |
Chen, CC | 1 |
Liu, CJ | 1 |
Chen, TJ | 1 |
Wu, JC | 1 |
Burn, J | 1 |
Sheth, H | 1 |
Coyle, C | 1 |
Cafferty, FH | 1 |
Rowley, S | 1 |
MacKenzie, M | 1 |
Berkman, L | 1 |
Gupta, S | 1 |
Pramesh, CS | 1 |
Gilbert, D | 1 |
Kynaston, H | 1 |
Cameron, D | 1 |
Wilson, RH | 1 |
Ring, A | 1 |
Langley, RE | 1 |
Veeraputhiran, M | 1 |
Sundermeyer, M | 1 |
Levine, AJ | 3 |
Grau, MV | 3 |
Midttun, O | 1 |
Ueland, PM | 3 |
Tsang, S | 3 |
Munroe, D | 1 |
Ali, I | 1 |
Haile, RW | 2 |
Wallace, K | 1 |
Saibil, F | 2 |
Ahnen, D | 1 |
Cole, BF | 2 |
Munroe, DJ | 2 |
Ali, IU | 2 |
Ueland, P | 1 |
Gee, JR | 1 |
Jarrard, DF | 1 |
Bruskewitz, RC | 1 |
Moon, TD | 1 |
Hedican, SP | 1 |
Leverson, GE | 1 |
Nakada, SY | 1 |
Messing, EM | 1 |
Gao, F | 1 |
Tan, A | 1 |
Cao, Y | 1 |
Mo, Z | 1 |
Logan, RF | 5 |
Halabi, S | 1 |
Grainge, MJ | 4 |
Chaussade, S | 5 |
Sansbury, LB | 1 |
Gui, J | 1 |
McKeown-Eyssen, GE | 1 |
Burke, C | 1 |
Hazra, A | 1 |
Selhub, J | 1 |
Chao, WH | 1 |
Hunter, DJ | 1 |
Uzzan, B | 2 |
Martin, A | 3 |
Deyra, J | 3 |
Little, J | 4 |
Girard, B | 2 |
Bhattacharyya, M | 1 |
Girish, GV | 1 |
Ghosh, R | 1 |
Chakraborty, S | 1 |
Sinha, AK | 1 |
Mott, LA | 1 |
Arber, N | 1 |
Spicak, J | 1 |
Rácz, I | 1 |
Zavoral, M | 1 |
Breazna, A | 1 |
Gerletti, P | 1 |
Lechuga, MJ | 1 |
Collins, N | 1 |
Rosenstein, RB | 1 |
Eagle, CJ | 1 |
Levin, B | 1 |
Zaorsky, NG | 1 |
Buyyounouski, MK | 1 |
Li, T | 1 |
Horwitz, EM | 1 |
McCowan, C | 1 |
Munro, AJ | 1 |
Donnan, PT | 1 |
Steele, RJ | 1 |
Jullian, E | 1 |
Piednoir, B | 1 |
Couturier, D | 2 |
Coste, T | 2 |
Tangrea, JA | 1 |
Albert, PS | 1 |
Lanza, E | 2 |
Woodson, K | 1 |
Corle, D | 1 |
Hasson, M | 1 |
Burt, R | 1 |
Caan, B | 1 |
Paskett, E | 1 |
Iber, F | 1 |
Kikendall, JW | 2 |
Lance, P | 2 |
Shike, M | 2 |
Weissfeld, J | 1 |
Schatzkin, A | 2 |
RAMSAY, AG | 1 |
WHITE, DF | 1 |
Turris, SA | 1 |
Smith, S | 1 |
Salman, MC | 1 |
Ayhan, A | 1 |
Bratasz, A | 1 |
Weir, NM | 1 |
Parinandi, NL | 1 |
Zweier, JL | 1 |
Sridhar, R | 1 |
Ignarro, LJ | 1 |
Kuppusamy, P | 1 |
Buhk, JH | 1 |
Wellmer, A | 1 |
Knauth, M | 1 |
Hubner, RA | 3 |
Muir, KR | 4 |
Liu, JF | 3 |
Grainge, M | 1 |
Armitage, N | 1 |
Shepherd, V | 1 |
Popat, S | 1 |
Houlston, RS | 3 |
Topakian, R | 1 |
Nussbaumer, K | 1 |
Trenkler, J | 1 |
Aichner, FT | 1 |
Flossmann, E | 1 |
Rothwell, PM | 1 |
Shepherd, VC | 1 |
Armitage, NC | 1 |
Lundberg, GD | 1 |
Drake-Lee, AB | 1 |
Lowe, D | 1 |
Swanston, A | 1 |
Grace, A | 1 |
Enzmann, H | 1 |
Rieben, FW | 1 |
van Camp, C | 1 |
Clement, PA | 2 |
Olivotto, IA | 1 |
Weir, LM | 1 |
Kim-Sing, C | 1 |
Bajdik, CD | 1 |
Trevisan, CH | 1 |
Doll, CM | 1 |
Lam, WY | 1 |
Basco, VE | 1 |
Jackson, SM | 1 |
Freedman, LS | 1 |
Tangrea, J | 1 |
Cooper, MR | 1 |
Marshall, JR | 1 |
Murphy, PA | 1 |
Selby, JV | 1 |
Schade, RR | 1 |
Burt, RW | 1 |
Cahill, J | 1 |
Bours, V | 1 |
Jerusalem, G | 1 |
Fillet, G | 1 |
Schmid, M | 1 |
Göde, U | 1 |
Schäfer, D | 1 |
Wigand, ME | 1 |
Amar, YG | 1 |
Frenkiel, S | 1 |
Sobol, SE | 1 |
Di Rienzo, L | 1 |
Artuso, A | 1 |
Cerqua, N | 1 |
Yoon, H | 1 |
van der Veken, P | 1 |
Verstraelen, J | 1 |
Buisseret, T | 1 |
Cox, A | 1 |
Frécourt, N | 1 |
Kaufman, L | 1 |
Derde, MP | 1 |
Jäntti-Alanko, S | 1 |
Holopainen, E | 1 |
Malmberg, H | 1 |
Clinical Trials (9)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer[NCT03326791] | Phase 2/Phase 3 | 466 participants (Actual) | Interventional | 2017-12-15 | Active, not recruiting | ||
Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome[NCT02813824] | Phase 3 | 852 participants (Anticipated) | Interventional | 2017-11-14 | Recruiting | ||
A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)[NCT03192059] | Phase 2 | 43 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory[NCT00238238] | Phase 2 | 97 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas[NCT00486512] | Phase 3 | 350 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to The overall program was terminated) | ||
Aspirin/Folate Prevention of Large Bowel Polyps[NCT00272324] | Phase 2/Phase 3 | 1,121 participants | Interventional | 1992-02-29 | Completed | ||
Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence[NCT00224679] | Phase 3 | 300 participants | Interventional | 1997-03-31 | Terminated | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Overall Response Rate
Response is assessed by investigator according to International Working Group (IWG) criteria. A complete response requires disappearance of all evidence of disease. A partial response is a >/= 50% decrease in the sum of products of 6 largest dominant nodes or nodal masses as well as for splenic and hepatic nodules. No increase in size of nodes, liver or spleen and no new sites of disease. (NCT00238238)
Timeframe: Duration of treatment (12 cycles)
Intervention | percentage of participants (Number) |
---|---|
Arm II - Lenalidomide | 53.3 |
Arm III - Lenalidomide and Rituximab | 76.1 |
Time to Progression
Time to progression (TTP) is defined as the time from study entry until progression or death without progression. The median TTP with 95% CI was estimated using the Kaplan-Meier method. (NCT00238238)
Timeframe: Up to 10 years
Intervention | years (Median) |
---|---|
Arm II - Lenalidomide | 1.1 |
Arm III - Lenalidomide and Rituximab | 2 |
Reviews
17 reviews available for aspirin and Local Neoplasm Recurrence
Article | Year |
---|---|
The multiple effects of aspirin in prostate cancer patients.
Topics: Aspirin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; D | 2021 |
AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review.
Topics: Aspirin; Chemoprevention; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Neoplasm Recurren | 2021 |
Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Incidence; Neoplasm | 2021 |
Head and neck cancer and non-steroidal anti-inflammatory drugs: Systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Head and Neck Neoplasms; Humans; Neoplasm Recurren | 2021 |
Effect of aspirin use on survival benefits of breast cancer patients: A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Neoplasm Recurre | 2021 |
Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy.
Topics: Aspirin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Humans; H | 2017 |
Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.
Topics: Adenoma; Anti-Inflammatory Agents; Aspirin; Colorectal Neoplasms; Humans; Incidence; Neoplasm Recurr | 2017 |
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Ce | 2018 |
Update on breast cancer risk prediction and prevention.
Topics: Age of Onset; Aromatase Inhibitors; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Diphosphonates; Fe | 2015 |
Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Female; Humans; Neoplasm Recurre | 2015 |
The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Neoplasm Re | 2016 |
The role of aspirin in preventing colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Gastrointestinal Hemorrhage; | 2016 |
The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans; Neoplasm Recurrence, Loca | 2009 |
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal | 2009 |
What every emergency nurse needs to know about aspirin.
Topics: Aspirin; Colorectal Neoplasms; Coronary Disease; Delayed-Action Preparations; Drug Administration Sc | 2005 |
Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Case-Co | 2005 |
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal | 2007 |
Trials
25 trials available for aspirin and Local Neoplasm Recurrence
Article | Year |
---|---|
Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial.
Topics: Aspirin; Colorectal Neoplasms; Double-Blind Method; Humans; Liver Neoplasms; Multicenter Studies as | 2021 |
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Neoplasm Recu | 2023 |
Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial).
Topics: Adult; Aged; Aspirin; Colorectal Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; | 2019 |
Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial.
Topics: Adenoma; Adult; Aspirin; Chemoprevention; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Non | 2020 |
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control St | 2021 |
Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Class I Phosphatidylinositol 3-Kinases; Col | 2018 |
PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aspirin; Chemoradiotherapy; Curcumin; Cycl | 2019 |
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adju | 2013 |
The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Alcohol Drinking; Anticarcinogenic Agents; Aspirin; Colonic Ne | 2014 |
Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).
Topics: Adenoma; Administration, Oral; Aged; Aspirin; Chromatography, Gas; Chromatography, Liquid; Colonosco | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial.
Topics: Adenoma; Adult; Aged; Aspirin; Calcitriol; Calcium; Chemoprevention; Colectomy; Colorectal Neoplasms | 2016 |
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemotherapy, Adjuvant; Colorect | 2016 |
Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.
Topics: Adenoma; Alcohol Drinking; Aspirin; Chemoprevention; Colorectal Neoplasms; Double-Blind Method; Fema | 2008 |
MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial.
Topics: Adenoma; Alleles; Aspirin; Chi-Square Distribution; Colorectal Neoplasms; Double-Blind Method; Femal | 2008 |
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Topics: Adenoma; Aged; Aspirin; Cohort Studies; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2009 |
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Topics: Adenoma; Adolescent; Adult; Aged; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Colorectal Ne | 2010 |
Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Double-Blind Method; Folic A | 2010 |
Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.
Topics: Adenomatous Polyposis Coli; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Aspirin; Col | 2011 |
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neopla | 2003 |
Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Genetic Pre | 2006 |
Aspirin and folic acid for the prevention of recurrent colorectal adenomas.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; Colo | 2008 |
Late cosmetic results of short fractionation for breast conservation.
Topics: Aspirin; Breast; Breast Neoplasms; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle | 1996 |
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics.
Topics: Adenoma; Adenomatous Polyps; Adult; Aspirin; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Demogra | 1996 |
APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings.
Topics: Adenoma; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colono | 2001 |
Other Studies
53 other studies available for aspirin and Local Neoplasm Recurrence
Article | Year |
---|---|
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) sensitize melanoma cells to MEK inhibition and inhibit metastasis and relapse by inducing degradation of AXL.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Humans; Melanoma; Mitogen-Activa | 2022 |
Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin?
Topics: Adjuvants, Immunologic; Administration, Intravesical; Anticoagulants; Aspirin; BCG Vaccine; Clopidog | 2022 |
Multiple cerebral infarctions due to calcified amorphous tumor growing rapidly from an antecedent infection and decreasing rapidly by detachment of fibrin and antithrombotic drugs: a case report.
Topics: Anti-Bacterial Agents; Aspirin; Calcinosis; Calcium; Cerebral Infarction; Female; Fibrin; Fibrinolyt | 2022 |
Ticagrelor Aspirin vs Clopidogrel Aspirin in
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Huma | 2023 |
Aspirin-Loaded Cross-Linked Lipoic Acid Nanodrug Prevents Postoperative Tumor Recurrence by Residual Cancer Cell Killing and Inflammatory Microenvironment Improvement.
Topics: Antineoplastic Agents; Aspirin; Cell Death; Cell Line, Tumor; Cisplatin; Humans; Nanoparticles; Neop | 2023 |
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspi | 2020 |
Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamou | 2018 |
Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.
Topics: Adrenergic beta-Antagonists; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Anti-Infl | 2018 |
NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; | 2018 |
The Association of Aspirin Use with Survival Following Radical Cystectomy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cystectomy; Disease-Free Survival; Female; F | 2018 |
No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2018 |
Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention.
Topics: Anti-Inflammatory Agents; Apoptosis; Aspirin; Cell Line, Tumor; Doxorubicin; Drug Therapy, Combinati | 2019 |
Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Female; Hepatectomy; | 2020 |
The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Anticoagulants; Aspirin; BCG Vaccine; Clopidogrel; | 2013 |
Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Class I Phosphatidylinositol 3-Kinases; Colorectal | 2013 |
[Aspirin and PIK3CA mutation in colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Lactones; Ma | 2014 |
Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Aspirin; Capecitabin | 2014 |
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemother | 2015 |
Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Colorectal Neoplasms; Disease-Free Survival; | 2014 |
Endobronchial biopsies on aspirin and prasugrel.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biopsy, Needle; Bronchoscopy; Carcinoma, Squamous Cell; Cor | 2015 |
Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection.
Topics: Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasm | 2015 |
RE: Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Co | 2015 |
Response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Co | 2015 |
A Chemopreventive Cocktail on the Rocks.
Topics: Aspirin; Calcitriol; Calcium; Female; Humans; Male; Neoplasm Recurrence, Local; Secondary Prevention | 2016 |
Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer.
Topics: Aged; Aspirin; Biliary Tract Neoplasms; Cardiovascular Agents; Comorbidity; Disease Progression; Dis | 2015 |
Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2016 |
Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection.
Topics: Adult; Aged; Aspirin; Carcinoma, Hepatocellular; Clopidogrel; Disease-Free Survival; Female; Gastroi | 2016 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensiv | 2008 |
Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
Topics: Administration, Intravesical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2009 |
Uracil misincorporation into DNA and folic acid supplementation.
Topics: Adenoma; Aged; Alcohol Drinking; Aspirin; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; DN | 2010 |
COX-2 expression in adenoma: an imperfect marker for chemoprevention.
Topics: Adenoma; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 | 2010 |
Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected].
Topics: Adult; Aged; Aspirin; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm R | 2010 |
Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Antineoplastic | 2012 |
Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Cause o | 2013 |
Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States).
Topics: Adenoma; Adenomatous Polyps; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; As | 2003 |
PHENACETIN NEPHROPATHY.
Topics: Acidosis; Animals; Aspirin; Bacteriuria; Biological Transport; Caffeine; Codeine; Dogs; Drug Therapy | 1965 |
Use of anti-thrombotic agents during chemotherapy for epithelial ovarian cancer.
Topics: Antineoplastic Agents; Aspirin; Drug Combinations; Female; Fibrinolytic Agents; Humans; Neoplasm Rec | 2006 |
Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Cell Proliferation; Cisplatin; D | 2006 |
Late in-stent thrombosis following carotid angioplasty and stenting.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Anticoagulants; Aph | 2006 |
Late in-stent thrombosis following carotid angioplasty and stenting.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Anticoagulants; Aph | 2007 |
Chemoprevention for colorectal cancer: some progress but a long way to go.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Folic Acid; Hematinics; Huma | 2008 |
Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.
Topics: Adenoma; Adult; Aged; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Female; Genes, APC; Ge | 2008 |
Aspirin helps prevent recurring colorectal adenomas--folic acid does not.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; Colo | 2008 |
Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence.
Topics: Adenoma; Adult; Aged; Animals; Aspirin; Calcium Compounds; Colorectal Neoplasms; Dairy Products; Fem | 2008 |
Clinical profile and recurrence of nasal polyps.
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Eczema; Female; Humans; Male; Middl | 1984 |
[Rhinosinusitis polyposa and intolerance to analgesics (aspirin intolerance)].
Topics: Adult; Aged; Analgesics; Aspirin; Bronchial Provocation Tests; Drug Hypersensitivity; Drug Tolerance | 1983 |
Results of oral steroid treatment in nasal polyposis.
Topics: Administration, Oral; Adult; Aged; Aspirin; Combined Modality Therapy; Drug Hypersensitivity; Female | 1994 |
[How I treat colorectal cancer. I. Prevention and adjuvant treatment].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antimeta | 1998 |
Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Asthma; Bronchial Provoca | 1999 |
Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter's triad.
Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease | 2000 |
[Antileukotrienes in the prevention of postoperative recurrence of nasal polyposis in ASA syndrome].
Topics: Acetates; Adult; Aged; Aspirin; Asthma; Cyclopropanes; Drug Hypersensitivity; Female; Humans; Leukot | 2000 |
Recurrent polyposis nasi. Documentation.
Topics: Adult; Aged; Airway Resistance; Aspirin; Female; Humans; Male; Middle Aged; Nasal Polyps; Nasal Prov | 1989 |
Recurrence of nasal polyps after surgical treatment.
Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Drug Hypersensitivity; Ethmoid Sinus; Follow-Up Studies; H | 1989 |